NCT07668648 Interscalene Brachial Plexus Block Versus Serratus Posterior Superior Intercostal Plane Block for Arthroscopic Shoulder Surgery
| NCT ID | NCT07668648 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ferit Yetik |
| Condition | Postoperative Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-06-25 |
| Primary Completion | 2026-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-06-25 with a primary completion date of 2026-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Arthroscopic shoulder surgery is associated with moderate to severe postoperative pain that may delay recovery and rehabilitation. Interscalene brachial plexus block (ISB) is widely used for postoperative analgesia in shoulder surgery; however, it may be associated with complications such as phrenic nerve paralysis. The serratus posterior superior intercostal plane (SPSIP) block is a recently described fascial plane block that may provide effective analgesia while avoiding some of the limitations of ISB. This prospective, randomized, double-blind controlled trial aims to compare the analgesic efficacy of ISB and SPSIP block in patients undergoing elective arthroscopic shoulder surgery under general anesthesia. The primary outcome is total postoperative opioid consumption during the first 24 hours after surgery. Secondary outcomes include postoperative pain scores, quality of recovery, time to first rescue analgesia, rescue analgesic requirements, intraoperative opioid consumption, sensory block distribution, motor block characteristics, and block-related complications.
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 75 years * ASA physical status I, II, or III * Scheduled for elective arthroscopic shoulder surgery under general anesthesia * Provision of written informed consent Exclusion Criteria: * Refusal to participate in the study * Coagulopathy * Current anticoagulant therapy * Infection at the block site * Previous surgery involving the planned block site * Known allergy or history of toxicity to local anesthetics * Hepatic failure * Renal failure * Uncontrolled diabetes mellitus * Cognitive impairment or mental disability preventing reliable assessment * Chronic opioid use or ongoing chronic pain treatment * Pregnancy, suspected pregnancy, or breastfeeding * Chronic pulmonary disease (e.g., COPD or asthma) * Failed block
Contact & Investigator
Mürsel Ekinci
PRINCIPAL INVESTIGATOR
University of Health Sciences, Bursa Faculty of Medicine, Bursa City Hospital
Frequently Asked Questions
Who can join the NCT07668648 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07668648 currently recruiting?
Yes, NCT07668648 is actively recruiting participants. Contact the research team at drmurselekinci@gmail.com for enrollment information.
Where is the NCT07668648 trial being conducted?
This trial is being conducted at Bursa, Turkey (Türkiye).
Who is sponsoring the NCT07668648 clinical trial?
NCT07668648 is sponsored by Ferit Yetik. The principal investigator is Mürsel Ekinci at University of Health Sciences, Bursa Faculty of Medicine, Bursa City Hospital. The trial plans to enroll 80 participants.